PEOPLE - Q-MED makes appointment:
This article was originally published in Clinica
The medical implants producer Q-MED based in Uppsala, Sweden, has appointed Mark van Rossum as sales director of its UK hospital healthcare division. Q-MED gel implants are based on the company's patented non-animal stabilised hyaluronic acid technology (NASHA) and are targeted at treatment of osteoarthritis of the knee and hip joints; female urinary incontinence; and vesicoureteral reflux in children.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.